Protalix updates on Elfabrio approvals, PRX-115 Phase I progress, and pipeline

Protalix BioTherapeutics, Inc.

Elfabrio (Fabry disease) approved by FDA and EMA; launched in US, EU, UK via Chiesi partnership.
Phase I trial of PRX-115 (gout) completed 7th cohort with 56 patients dosed; completion expected Q2 2024.
Preclinical development advancing for PRX-119 (DNase I for NETs-related diseases).
CEO acknowledges ongoing challenges in Israel, reaffirms commitment to operations and pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.